Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Esophageal Cancer
Interventions
DRUG

Utidelone and anlotinib

"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."

Trial Locations (3)

453100

NOT_YET_RECRUITING

The First Affiliated Hospital of Xinxiang Medical University, Weihui

629000

NOT_YET_RECRUITING

Suining Central Hospital, Suining

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing, China, Beijing

All Listed Sponsors
collaborator

Beijing Biostar Pharmaceuticals Co., Ltd.

INDUSTRY

collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Peking University

OTHER